Consistently, cell survival assays on KYSE-410 and KYSE-30 cell groups under the treatment of 5-FU, cisplatin, or paclitaxel indicated that TRIM9 shRNA-treated tumor cells exhibited a significantly increased survival rate compared with the control group (Figure 3(c)), whereas TRIM9 overexpression vector-transfected tumor cells demonstrated notably decreased cell survival (Figure 3(d)). This evidence concerns the gene TRIM9 and neoplasm.